299 related articles for article (PubMed ID: 25673725)
1. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.
Shimizu Y; Shirasago Y; Kondoh M; Suzuki T; Wakita T; Hanada K; Yagi K; Fukasawa M
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437969
[TBL] [Abstract][Full Text] [Related]
3. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.
Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
Fofana I; Krieger SE; Grunert F; Glauben S; Xiao F; Fafi-Kremer S; Soulier E; Royer C; Thumann C; Mee CJ; McKeating JA; Dragic T; Pessaux P; Stoll-Keller F; Schuster C; Thompson J; Baumert TF
Gastroenterology; 2010 Sep; 139(3):953-64, 964.e1-4. PubMed ID: 20685314
[TBL] [Abstract][Full Text] [Related]
5. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.
Paciello R; Urbanowicz RA; Riccio G; Sasso E; McClure CP; Zambrano N; Ball JK; Cortese R; Nicosia A; De Lorenzo C
J Gen Virol; 2016 Jan; 97(1):82-94. PubMed ID: 26519290
[TBL] [Abstract][Full Text] [Related]
6. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
[TBL] [Abstract][Full Text] [Related]
7. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF
Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099
[TBL] [Abstract][Full Text] [Related]
8. Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.
Tawar RG; Colpitts CC; Timm J; Fehm T; Roggendorf M; Meisel H; Meyer N; Habersetzer F; Cosset FL; Berg T; Zeisel MB; Baumert TF
Hepatology; 2015 Sep; 62(3):726-36. PubMed ID: 26010076
[TBL] [Abstract][Full Text] [Related]
9. Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.
Riva L; Song OR; Prentoe J; Helle F; L'homme L; Gattolliat CH; Vandeputte A; Fénéant L; Belouzard S; Baumert TF; Asselah T; Bukh J; Brodin P; Cocquerel L; Rouillé Y; Dubuisson J
J Virol; 2018 May; 92(10):. PubMed ID: 29491159
[TBL] [Abstract][Full Text] [Related]
10. A human claudin-1-derived peptide inhibits hepatitis C virus entry.
Si Y; Liu S; Liu X; Jacobs JL; Cheng M; Niu Y; Jin Q; Wang T; Yang W
Hepatology; 2012 Aug; 56(2):507-15. PubMed ID: 22378192
[TBL] [Abstract][Full Text] [Related]
11. Use of Modified
Beier LS; Rossa J; Woodhouse S; Bergmann S; Kramer HB; Protze J; Eichner M; Piontek A; Vidal-Y-Sy S; Brandner JM; Krause G; Zitzmann N; Piontek J
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561440
[TBL] [Abstract][Full Text] [Related]
12. Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line.
Haid S; Windisch MP; Bartenschlager R; Pietschmann T
J Virol; 2010 Jan; 84(2):964-75. PubMed ID: 19889758
[TBL] [Abstract][Full Text] [Related]
13. [Claudin 1 as a target for anti-hepatitis C virus strategy].
Fukasawa M
Yakugaku Zasshi; 2014; 134(5):635-40. PubMed ID: 24790046
[TBL] [Abstract][Full Text] [Related]
14. Isolate-dependent use of claudins for cell entry by hepatitis C virus.
Haid S; Grethe C; Dill MT; Heim M; Kaderali L; Pietschmann T
Hepatology; 2014 Jan; 59(1):24-34. PubMed ID: 23775920
[TBL] [Abstract][Full Text] [Related]
15. [Anti-hepatitis C Virus Strategy Targeting the Entry Steps].
Fukasawa M
Yakugaku Zasshi; 2019; 139(1):89-95. PubMed ID: 30606936
[TBL] [Abstract][Full Text] [Related]
16. Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins.
Hopcraft SE; Evans MJ
Hepatology; 2015 Oct; 62(4):1059-69. PubMed ID: 25820616
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.
Krieger SE; Zeisel MB; Davis C; Thumann C; Harris HJ; Schnober EK; Mee C; Soulier E; Royer C; Lambotin M; Grunert F; Dao Thi VL; Dreux M; Cosset FL; McKeating JA; Schuster C; Baumert TF
Hepatology; 2010 Apr; 51(4):1144-57. PubMed ID: 20069648
[TBL] [Abstract][Full Text] [Related]
18. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
[TBL] [Abstract][Full Text] [Related]
19. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry.
Harris HJ; Farquhar MJ; Mee CJ; Davis C; Reynolds GM; Jennings A; Hu K; Yuan F; Deng H; Hubscher SG; Han JH; Balfe P; McKeating JA
J Virol; 2008 May; 82(10):5007-20. PubMed ID: 18337570
[TBL] [Abstract][Full Text] [Related]
20. Dual blockade of hepatitis C virus entry at a gatekeeper of hepatocytes: Not only a preventive, but also therapeutic target of claudin 1.
Sugiyama M; Kanto T
Hepatology; 2016 Sep; 64(3):979-82. PubMed ID: 27405253
[No Abstract] [Full Text] [Related]
[Next] [New Search]
